Kevin J Duffy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5833750/publications.pdf

Version: 2024-02-01

304602 3,157 33 22 h-index citations papers

g-index 36 36 36 4630 docs citations times ranked citing authors all docs

395590

33

#	Article	IF	CITATIONS
1	Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature, 2018, 564, 439-443.	13.7	505
2	Targeting Lactate Dehydrogenase-A Inhibits Tumorigenesis and Tumor Progression in Mouse Models of Lung Cancer and Impacts Tumor-Initiating Cells. Cell Metabolism, 2014, 19, 795-809.	7.2	411
3	Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist. Stem Cells, 2009, 27, 424-430.	1.4	243
4	Identification and Biological Characterization of Heterocyclic Inhibitors of the Hepatitis C Virus RNA-dependent RNA Polymerase. Journal of Biological Chemistry, 2002, 277, 38322-38327.	1.6	190
5	Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Experimental Hematology, 2005, 33, 85-93.	0.2	176
6	Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer & Metabolism, 2013, 1, 19.	2.4	163
7	3-(1,1-Dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, Potent Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase. Journal of Medicinal Chemistry, 2006, 49, 971-983.	2.9	157
8	Endothelial HIF-2 mediates protection and recovery from ischemic kidney injury. Journal of Clinical Investigation, 2014, 124, 2396-2409.	3.9	150
9	Total Synthesis of Altohyrtin A (Spongistatin 1): Part 1. Angewandte Chemie - International Edition, 1998, 37, 187-190.	7.2	130
10	Hydrazinonaphthalene and Azonaphthalene Thrombopoietin Mimics Are Nonpeptidyl Promoters of Megakaryocytopoiesis. Journal of Medicinal Chemistry, 2001, 44, 3730-3745.	2.9	106
11	Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury. American Journal of Physiology - Renal Physiology, 2012, 302, F1172-F1179.	1.3	104
12	Resistance Profile of a Hepatitis C Virus RNA-Dependent RNA Polymerase Benzothiadiazine Inhibitor. Antimicrobial Agents and Chemotherapy, 2003, 47, 3525-3530.	1.4	95
13	Chronic Inhibition of Hypoxia-inducible Factor Prolyl 4-hydroxylase Improves Ventricular Performance, Remodeling, and Vascularity After Myocardial Infarction in the Rat. Journal of Cardiovascular Pharmacology, 2010, 56, 147-155.	0.8	84
14	Identification of a Pharmacophore for Thrombopoietic Activity of Small, Non-Peptidyl Molecules. 1. Discovery and Optimization of Salicylaldehyde Thiosemicarbazone Thrombopoietin Mimics. Journal of Medicinal Chemistry, 2002, 45, 3573-3575.	2.9	83
15	Novel ATP-Competitive Kinesin Spindle Protein Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 4939-4952.	2.9	7 3
16	Arresting Initiation of Hepatitis C Virus RNA Synthesis Using Heterocyclic Derivatives. Journal of Biological Chemistry, 2003, 278, 16602-16607.	1.6	65
17	Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor–Prolyl Hydroxylase Inhibitor for Anemia. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 336-347.	1.3	65
18	Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295. ACS Medicinal Chemistry Letters, 2010, 1, 30-34.	1.3	54

#	Article	IF	CITATIONS
19	Identification of a Pharmacophore for Thrombopoietic Activity of Small, Non-Peptidyl Molecules. 2. Rational Design of Naphtho $[1,2-d]$ imidazole Thrombopoietin Mimics. Journal of Medicinal Chemistry, 2002, 45, 3576-3578.	2.9	53
20	Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4350-4353.	1.0	43
21	A Highly Efficient, Asymmetric Synthesis of Benzothiadiazine-Substituted Tetramic Acids:  Potent Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase. Organic Letters, 2005, 7, 5521-5524.	2.4	36
22	Synthesis and biological activity of heteroaryl 3- $(1,1-dioxo-2H-(1,2,4)-benzothiadizin-3-yl)-4-hydroxy-2(1H)-quinolinone derivatives as hepatitis C virus NS5B polymerase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4354-4358.$	1.0	24
23	Biochemical Characterization of Human Prolyl Hydroxylase Domain Protein 2 Variants Associated with Erythrocytosis. Biochemistry, 2008, 47, 11165-11167.	1.2	23
24	Species Specificity and Receptor Domain Interaction of a Small Molecule TPO Receptor Agonist Blood, 2004, 104, 2909-2909.	0.6	20
25	Design and synthesis of diaminopyrrolidinone inhibitors of human osteoclast cathepsin K. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 1907-1910.	1.0	17
26	Selective Binding and Oligomerization of the Murine Granulocyte Colony-stimulating Factor Receptor by a Low Molecular Weight, Nonpeptidyl Ligand. Journal of Biological Chemistry, 2003, 278, 9426-9434.	1.6	15
27	Discovery of SB-497115, a Small-Molecule Thrombopoietin (TPO) Receptor Agonist for the Treatment of Thrombocytopenia Blood, 2004, 104, 2910-2910.	0.6	15
28	Biological Activity and Selectivity for Tpo Receptor of the Orally Bioavailable, Small Molecule Tpo Receptor Agonist, SB-497115 Blood, 2004, 104, 2912-2912.	0.6	11
29	STING Activation and its Application in Immuno-Oncology. Current Topics in Medicinal Chemistry, 2019, 19, 2205-2227.	1.0	11
30	The scope and mechanism of a novel synthesis of 3,4-fused isoxazoles. Journal of the Chemical Society Chemical Communications, 1995, , 2457.	2.0	8
31	THE DISCOVERY OF ELTROMBOPAG, AN ORALLY BIOAVAILABLE TPOR AGONIST. , 2007, , 241-254.		8
32	A novel synthesis of 2-(2-quinoxalino)-3,5-diarylfurans. Tetrahedron Letters, 1998, 39, 8017-8020.	0.7	7
33	GSK626616: A DYRK3 Inhibitor as a Potential New Therapy for the Treatment of Anemia Blood, 2007, 110, 510-510.	0.6	5